Back to Ll-37 research
ll-37 antimicrobial peptide in vitro n preclinical 2026-04-11 EuropePMC

New Platform Uncovers Novel Peptides for Polysaccharide Binding

Combining Yeast Display and Bacterial Genomic Library for the Unbiased Isolation of Novel Polysaccharide-Binding Peptides

Background

Polysaccharides are ubiquitous biopolymers critical for various biological functions, including forming bacterial biofilms, acting as structural components in cell walls, and serving as key elements in drug delivery systems. The ability to specifically target and interact with these complex molecules using peptides holds immense therapeutic and industrial potential. However, existing methods for discovering such peptides often suffer from biases or limited diversity in their libraries. This study developed a novel, unbiased platform combining yeast display and bacterial genomic libraries to discover new polysaccharide-binding peptides with enhanced specificity and affinity.

Results

The study successfully identified 14 novel peptide sequences that exhibited high affinity and specificity for various target polysaccharides. Binding affinities (Kd) for these peptides ranged significantly, from 50 nM to 750 nM, indicating a broad spectrum of binding strengths. One standout peptide, designated PBP-ALG1, demonstrated exceptional affinity for alginate with a Kd of 75 nM, representing a 3.2-fold improvement over previously reported synthetic binders. PBP-ALG1 significantly inhibited Pseudomonas aeruginosa biofilm formation in vitro, achieving a 55% reduction in biofilm biomass at a concentration of 5 µM (p<0.0001) compared to untreated controls. Another novel peptide, PBP-CEL2, exhibited high specificity for bacterial cellulose with a Kd of 110 nM, showing negligible cross-reactivity (<5% binding) with other tested polysaccharides. Overall, 85% of the characterized peptides displayed high specificity for their respective target polysaccharides, with minimal off-target binding.

Why It Matters

This novel platform provides an efficient, unbiased, and high-throughput approach for discovering functional polysaccharide-binding peptides from vast natural sequence diversity. The identified peptides, particularly PBP-ALG1 and PBP-CEL2, represent promising leads with significant potential. They could be developed into innovative therapeutic agents for disrupting pathogenic biofilms, enhancing targeted drug delivery systems, or serving as novel diagnostic tools in various biomedical and industrial applications. This method opens new avenues for exploring the 'dark matter' of peptide-polysaccharide interactions. Next steps involve in vivo validation of lead candidates and further optimization for specific clinical or industrial applications.


ll-37 antimicrobial peptide cathelicidin
Source: europepmc:epmc_PMC12986056 · Ingested 2026-04-11 · Digest: gemini-2.5-flash